Glicef-T (Ceftriaxone + Tazobactam 1.125 g Injection)

Overview:

GLICEF-T Injection contains Ceftrixone and Tazobactam. Ceftriaxone is broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability. Ceftriaxone has an activity against gram-positive and gram-negative aerobic and anaerobic bacteria. Tazobactam inhibits the action of bacterial beta-lactamases.


Ceftriaxone sodium is a broad-spectrum bactericidal cephalosporin antibiotic. Tazobactam belongs to penicillanic acid sulfone derivative and beta-lactamase inhibitor with antibacterial activity.
Antibacterial.

GLICEF-T Injection can be used in the treatment of following conditions:

  • Lower respiratory tract infections
  • Acute bacterial otitis media
  • Skin and skin structure infections
  • UTIs and uncomplicated gonorrhea
  • Pelvic inflammatory disease
  • Bacterial septicemia, meningitis
  • Bone and joint infections
  • Intra-abdominal infections
  • Surgical prophylaxis


One GLICEF-T Injection is administered once a day (or in equally divided doses twice a day depending on the type of infection) for 7-14 days; longer treatment may be needed in more serious infections.

Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in the cell-wall synthesis and cell division by binding to these enzymes, Ceftriaxone results in the formation of defective cell walls and cell death. Tazobactam broadens the spectrum by making it effective against organisms that express beta-lactamase.